Skip to content
2000
Volume 33, Issue 6
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a promising and innovative approach, demonstrating favorable clinical potential in the treatment of these disorders. Although preliminary studies have confirmed its therapeutic efficacy, a comprehensive and systematic analysis of the research trends and current limitations of MDMA-AT remains lacking.

Methods

This study employed a bibliometric approach to systematically retrieve and analyze research literature published between 1994 and 2023 on the application of MDMA in the treatment of PTSD, anxiety, and depression. Relevant data were obtained from three prominent databases: Web of Science Core Collection, PubMed, and Scopus. VOSviewer and Microsoft Excel were used to perform visual and quantitative analyses, focusing on publication trends, research hotspots, prolific authors, leading institutions, and international collaboration networks.

Results

The findings indicated a substantial increase in MDMA-related research over the past decade. The United States has led the field in publication output, with the Multidisciplinary Association for Psychedelic Studies (MAPS) identified as the most productive institution. Key figures, such as Rick Doblin, have demonstrated high influence and centrality within the global research network. The research focus has gradually shifted from investigations of the neurotoxic properties of MDMA to explorations of its therapeutic mechanisms, safety profiles, and clinical applications.

Conclusion

This study provides a comprehensive synthesis of the past thirty years of research on MDMA-AT in the treatment of PTSD, anxiety, and depression, identifying major research trajectories and critical challenges in the field. While current findings highlight the therapeutic promise of MDMA and its translational potential, further research is needed to improve trial design, enhance sample diversity, and evaluate long-term effects in order to support the standardization and evidence-based integration of MDMA-assisted therapy into clinical practice.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673359474250511181821
2025-06-02
2026-03-05

  • From This Site

    /content/journals/cmc/10.2174/0109298673359474250511181821
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SchäferS.K. ThomasL.M. LindnerS. LiebK. World Health Organization’s low-intensity psychosocial interventions: a systematic review and meta-analysis of the effects of Problem Management Plus and Step-by-Step.World Psychiatry202322344946210.1002/wps.2112937713578
     [Google Scholar]
  2. ParianteC.M. LightmanS.L. The HPA axis in major depression: classical theories and new developments.Trends Neurosci.200831946446810.1016/j.tins.2008.06.00618675469
     [Google Scholar]
  3. BalducciC. FrascaA. ZottiM. La VitolaP. MhillajE. GrigoliE. IacobellisM. GrandiF. MessaM. ColomboL. MolteniM. TrabaceL. RossettiC. SalmonaM. ForloniG. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer’s disease.Brain Behav. Immun.20176018819710.1016/j.bbi.2016.10.01227751869
     [Google Scholar]
  4. WangH. XiaoL. WangH. WangG. Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model.Physiol. Behav.202021511274910.1016/j.physbeh.2019.11274931770536
     [Google Scholar]
  5. PfefferbaumB. Posttraumatic Stress Disorder in Children in the Context of the COVID-19 Pandemic.J. Am. Acad. Child Adolesc. Psychiatry202261895795910.1016/j.jaac.2022.02.00735219806
     [Google Scholar]
  6. WadeD.M. BrewinC.R. HowellD.C.J. WhiteE. MythenM.G. WeinmanJ.A. Intrusive memories of hallucinations and delusions in traumatized intensive care patients: An interview study.Br. J. Health Psychol.201520361363110.1111/bjhp.1210924944013
     [Google Scholar]
  7. BrewinC.R. GregoryJ.D. LiptonM. BurgessN. Intrusive images in psychological disorders: Characteristics, neural mechanisms, and treatment implications.Psychol. Rev.2010117121023210.1037/a001811320063969
     [Google Scholar]
  8. ZerbinattiC.V. WahrleS.E. KimH. CamJ.A. BalesK. PaulS.M. HoltzmanD.M. BuG. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice.J. Biol. Chem.200628147361803618610.1074/jbc.M60443620017012232
     [Google Scholar]
  9. NathS. AgholmeL. KurudenkandyF.R. GransethB. MarcussonJ. HallbeckM. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid.J. Neurosci.201232268767877710.1523/JNEUROSCI.0615‑12.201222745479
     [Google Scholar]
  10. YangW.N. MaK.G. QianY.H. ZhangJ.S. FengG.F. ShiL.L. ZhangZ.C. LiuZ.H. Mitogen-activated protein kinase signaling pathways promote low-density lipoprotein receptor-related protein 1-mediated internalization of beta-amyloid protein in primary cortical neurons.Int. J. Biochem. Cell Biol.20156425226410.1016/j.biocel.2015.04.01325936756
     [Google Scholar]
  11. PattonS.C. WatkinsL.E. KilleenT.K. HienD.A. Posttraumatic stress disorder and substance use disorder screening, assessment, and treatment.Curr. Psychiatry Rep.2024261284385110.1007/s11920‑024‑01547‑839407067
     [Google Scholar]
  12. ZhuY. JhaS.C. ShuttaK.H. HuangT. BalasubramanianR. ClishC.B. HankinsonS.E. KubzanskyL.D. Psychological distress and metabolomic markers: A systematic review of posttraumatic stress disorder, anxiety, and subclinical distress.Neurosci. Biobehav. Rev.202214310495410.1016/j.neubiorev.2022.10495436368524
     [Google Scholar]
  13. CohenB.E. EdmondsonD. KronishI.M. State of the art review: Depression, stress, anxiety, and cardiovascular disease.Am. J. Hypertens.201528111295130210.1093/ajh/hpv04725911639
     [Google Scholar]
  14. ZoladzP.R. DiamondD.M. Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature.Neurosci. Biobehav. Rev.201337586089510.1016/j.neubiorev.2013.03.02423567521
     [Google Scholar]
  15. AdamecR. HolmesA. BlundellJ. Vulnerability to lasting anxiogenic effects of brief exposure to predator stimuli: Sex, serotonin and other factors—relevance to PTSD.Neurosci. Biobehav. Rev.20083271287129210.1016/j.neubiorev.2008.05.00518550167
     [Google Scholar]
  16. LiM. YangX.K. YangJ. LiT.X. CuiC. PengX. LeiJ. RenK. MingJ. ZhangP. TianB. Ketamine ameliorates post-traumatic social avoidance by erasing the traumatic memory encoded in VTA-innervated BLA engram cells.Neuron20241121831923210.e610.1016/j.neuron.2024.06.02639032491
     [Google Scholar]
  17. NorredM.A. ZuschlagZ.D. HamnerM.B. A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder.Drugs202484214916410.1007/s40265‑023‑01983‑538413493
     [Google Scholar]
  18. Yazar-KlosinskiB.B. MithoeferM.C. Potential Psychiatric Uses for MDMA.Clin. Pharmacol. Ther.2017101219419610.1002/cpt.56527859039
     [Google Scholar]
  19. HealyD. ManginD. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence.Epidemiol. Psychiatr. Sci.202433e4010.1017/S204579602400044139289881
     [Google Scholar]
  20. HeinzM.V. Yom-TovE. MackinD.M. MatsumuraR. JacobsonN.C. A large-scale observational comparison of antidepressants and their effects.J. Psychiatr. Res.202417821922410.1016/j.jpsychires.2024.08.00139163659
     [Google Scholar]
  21. SlomskiA. MDMA-assisted therapy highly effective for PTSD.JAMA2021326429934313690
     [Google Scholar]
  22. GellerJ. WhitneyE. Therapeutic potential of MDMA- and psychedelic-assisted psychotherapy for adolescent depression and trauma.Curr. Psychiatry Rep.2024272889739699759
     [Google Scholar]
  23. KangaslampiS. ZijlmansJ. MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.Eur. Child Adolesc. Psychiatry202433113753376410.1007/s00787‑023‑02310‑937814082
     [Google Scholar]
  24. MithoeferM.C. WagnerM.T. MithoeferA.T. JeromeL. DoblinR. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.J. Psychopharmacol.201125443945210.1177/026988111037837120643699
     [Google Scholar]
  25. Ot’alora, G.M.; Grigsby, J.; Poulter, B.; Van Derveer, III J.W.; Giron, S.G.; Jerome, L.; Feduccia, A.A.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C. 3, 4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J. Psychopharmacol., 2018, 32(12), 1295-307.10.1177/026988111880629730371148
  26. MithoeferM.C. GrobC.S. BrewertonT.D. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.Lancet Psychiatry20163548148810.1016/S2215‑0366(15)00576‑327067625
     [Google Scholar]
  27. DanforthA.L. StrubleC.M. Yazar-KlosinskiB. GrobC.S. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.Prog. Neuropsychopharmacol. Biol. Psychiatry20166423724910.1016/j.pnpbp.2015.03.01125818246
     [Google Scholar]
  28. WolfgangA.S. FonzoG.A. GrayJ.C. KrystalJ.H. GrzendaA. WidgeA.S. KraguljacN.V. McDonaldW.M. RodriguezC.I. NemeroffC.B. MDMA and MDMA-Assisted Therapy.Am. J. Psychiatry202518217910310.1176/appi.ajp.2023068139741438
     [Google Scholar]
  29. de la TorreR. FarréM. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.Trends Pharmacol. Sci.2004251050550810.1016/j.tips.2004.08.00115380932
     [Google Scholar]
  30. HeX. LengZ. LiH. WangD. CaoK. Olfactory ensheathing cell transplantation for spinal cord injury: An 18-year bibliometric analysis based on the Web of Science.Neural Regen. Res.20138141286129610.4103/1673‑5374.12163025206423
     [Google Scholar]
  31. AlotaibiN.M. NassiriF. BadhiwalaJ.H. WitiwC.D. IbrahimG.M. MacdonaldR.L. LozanoA.M. The most cited works in aneurysmal subarachnoid hemorrhage: A bibliometric analysis of the 100 most cited articles.World Neurosurg.201689587592.e610.1016/j.wneu.2015.11.07226723285
     [Google Scholar]
  32. WangY. ChenQ. DangX. LuW. ZhangX. YanH. NiuS. YanX. YanJ. A bibliometric analysis on traumatic brain injury in forensic medicine of a half-century (1972–2021).Front. Neurol.20231491385510.3389/fneur.2023.91385536816552
     [Google Scholar]
  33. ChenC. SongM. Visualizing a field of research: A methodology of systematic scientometric reviews.PLoS One20191410e022399410.1371/journal.pone.022399431671124
     [Google Scholar]
  34. YeS. HuJ. LiuZ. LiangM. Progress and Research Trends on Catha edulis (Vahl) Endl. (Catha edulis): A Review and Bibliometric Analysis.Front. Pharmacol.20211270537610.3389/fphar.2021.70537634867319
     [Google Scholar]
  35. O’DonnellJ. GladdenR.M. MattsonC.L. HunterC.T. DavisN.L. Vital Signs: characteristics of drug overdose deaths involving opioids and stimulants — 24 states and the district of columbia, january–june 2019.MMWR Morb. Mortal. Wkly. Rep.202069351189119710.15585/mmwr.mm6935a132881854
     [Google Scholar]
  36. MithoeferM.C. MithoeferA.T. FeducciaA.A. JeromeL. WagnerM. WymerJ. HollandJ. HamiltonS. Yazar-KlosinskiB. EmersonA. DoblinR. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.Lancet Psychiatry20185648649710.1016/S2215‑0366(18)30135‑429728331
     [Google Scholar]
  37. MitchellJ.M. Ot’alora GM. van der KolkB. ShannonS. BogenschutzM. GelfandY. PaleosC. NicholasC.R. QuevedoS. BalliettB. HamiltonS. MithoeferM. KleimanS. Parker-GuilbertK. TzarfatyK. HarrisonC. de BoerA. DoblinR. Yazar-KlosinskiB. HarrisonC. Yazar-KlosinskiB. GarasW. MayD. MartaC. WalkerS. NielsonE. WellsG. BrownR. AmiazR. WallachY. WorthyR. LiliensteinA. EmersonA. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.Nat. Med.202329102473248010.1038/s41591‑023‑02565‑437709999
     [Google Scholar]
  38. MithoeferM.C. WagnerM.T. MithoeferA.T. JeromeL. MartinS.F. Yazar-KlosinskiB. MichelY. BrewertonT.D. DoblinR. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.J. Psychopharmacol.2013271283910.1177/026988111245661123172889
     [Google Scholar]
  39. SiegelA.N. MeshkatS. BenitahK. LipsitzO. GillH. LuiL.M.W. TeopizK.M. McIntyreR.S. RosenblatJ.D. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.J. Psychiatr. Res.2021139718110.1016/j.jpsychires.2021.05.01934048997
     [Google Scholar]
  40. BediG. CottonS.M. GuerinA.A. JacksonH.J. MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail.Aust. N. Z. J. Psychiatry202357447648110.1177/0004867422112718636165006
     [Google Scholar]
  41. DanforthA.L. GrobC.S. StrubleC. FeducciaA.A. WalkerN. JeromeL. Yazar-KlosinskiB. EmersonA. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.Psychopharmacology (Berl.)2018235113137314810.1007/s00213‑018‑5010‑930196397
     [Google Scholar]
  42. WolfsonP.E. AndriesJ. FeducciaA.A. JeromeL. WangJ.B. WilliamsE. CarlinS.C. SolaE. HamiltonS. Yazar-KlosinskiB. EmersonA. MithoeferM.C. DoblinR. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.Sci. Rep.20201012044210.1038/s41598‑020‑75706‑133235285
     [Google Scholar]
  43. SessaB. HigbedL. O’BrienS. DurantC. SakalC. TitheradgeD. WilliamsT.M. Rose-MorrisA. Brew-GirardE. BurrowsS. WisemanC. WilsonS. RickardJ. NuttD.J. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.J. Psychopharmacol.202135437538310.1177/026988112199179233601929
     [Google Scholar]
  44. GreenA.R. MechanA.O. ElliottJ.M. O’SheaE. ColadoM.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”).Pharmacol. Rev.200355346350810.1124/pr.55.3.312869661
     [Google Scholar]
  45. MoratallaR. KhairnarA. SimolaN. GranadoN. García-MontesJ.R. PorcedduP.F. TizabiY. CostaG. MorelliM. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms.Prog. Neurobiol.201715514917010.1016/j.pneurobio.2015.09.01126455459
     [Google Scholar]
  46. BaumannM.H. WangX. RothmanR.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Psychopharmacology (Berl.)2007189440742410.1007/s00213‑006‑0322‑616541247
     [Google Scholar]
  47. StoneD.M. HansonG.R. GibbJ.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.Neuropharmacology198726111657166110.1016/0028‑3908(87)90017‑72448703
     [Google Scholar]
  48. MuellerF. LenzC. SteinerM. DolderP.C. WalterM. LangU.E. LiechtiM.E. BorgwardtS. Neuroimaging in moderate MDMA use: A systematic review.Neurosci. Biobehav. Rev.201662213410.1016/j.neubiorev.2015.12.01026746590
     [Google Scholar]
  49. LiechtiM.E. BaumannC. GammaA. VollenweiderF.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram.Neuropsychopharmacology200022551352110.1016/S0893‑133X(99)00148‑710731626
     [Google Scholar]
  50. O’SheaE. EstebanB. CamareroJ. GreenA.R. ColadoM.I. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain.Neuropharmacology2001401657410.1016/S0028‑3908(00)00106‑411077072
     [Google Scholar]
  51. VizeliP. LiechtiM.E. No influence of dopamine system gene variations on acute effects of MDMA.Front. Psychiatry20191075510.3389/fpsyt.2019.0075531708815
     [Google Scholar]
  52. VegtingY. RenemanL. BooijJ. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.Psychopharmacology (Berl.)201623319-203473350110.1007/s00213‑016‑4396‑527568200
     [Google Scholar]
  53. KivellB. DayD. BoschP. SchenkS. MillerJ. MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation.Neuroscience20101681829510.1016/j.neuroscience.2010.03.01820298763
     [Google Scholar]
  54. BiezonskiD.K. MeyerJ.S. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.J. Neurochem.2010112495196210.1111/j.1471‑4159.2009.06515.x20002520
     [Google Scholar]
  55. GreenA.R. GabrielssonJ. MarsdenC.A. FoneK.C.F. MDMA: On the translation from rodent to human dosing.Psychopharmacology (Berl.)2009204237537810.1007/s00213‑008‑1453‑819139850
     [Google Scholar]
  56. NuttD. KingL.A. SaulsburyW. BlakemoreC. Development of a rational scale to assess the harm of drugs of potential misuse.Lancet200736995661047105310.1016/S0140‑6736(07)60464‑417382831
     [Google Scholar]
  57. NuttD.J. KingL.A. PhillipsL.D. Drug harms in the UK: a multicriteria decision analysis.Lancet201037697521558156510.1016/S0140‑6736(10)61462‑621036393
     [Google Scholar]
  58. VakdeT. DiazM. UdayK. DuncalfR. Rapidly reversible multiorgan failure after ingestion of “Molly” (pure 3,4-methylenedioxymethamphetamine): a case report.J. Med. Case Reports20148120410.1186/1752‑1947‑8‑20424942782
     [Google Scholar]
  59. ConnollyE. O’CallaghanG. MDMA toxicity presenting with severe hyperpyrexia: a case report.Crit. Care Resusc.19991436837010.1016/S1441‑2772(23)00628‑216599881
     [Google Scholar]
  60. Ghaffari-RafiA. EumK.S. VillanuevaJ. JahanmirJ. Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity.Medicine (Baltimore)20209941e2184210.1097/MD.000000000002184233031256
     [Google Scholar]
  61. HolzeF. VizeliP. MüllerF. LeyL. DuerigR. VargheseN. EckertA. BorgwardtS. LiechtiM.E. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects.Neuropsychopharmacology202045346247110.1038/s41386‑019‑0569‑331733631
     [Google Scholar]
  62. LiechtiM. SaurM.R. GammaA. HellD. VollenweiderF.X. Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.Neuropsychopharmacology200023439640410.1016/S0893‑133X(00)00126‑310989266
     [Google Scholar]
  63. MacInnesN. HandleyS.L. HardingG.F.A. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms.J. Psychopharmacol.200115318118610.1177/02698811010150031011565625
     [Google Scholar]
  64. ParrottA.C. SiskE. TurnerJ.J. Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users.Drug Alcohol Depend.200060110511010821995
     [Google Scholar]
  65. IllingworthB.J.G. LewisD.J. LambarthA.T. StockingK. DuffyJ.M.N. JelenL.A. RuckerJ.J. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.J. Psychopharmacol.202135550151110.1177/026988112096591533345689
     [Google Scholar]
  66. MitchellJ.M. BogenschutzM. LiliensteinA. HarrisonC. KleimanS. Parker-GuilbertK. Ot’alora GM. GarasW. PaleosC. GormanI. NicholasC. MithoeferM. CarlinS. PoulterB. MithoeferA. QuevedoS. WellsG. KlaireS.S. van der KolkB. TzarfatyK. AmiazR. WorthyR. ShannonS. WoolleyJ.D. MartaC. GelfandY. HapkeE. AmarS. WallachY. BrownR. HamiltonS. WangJ.B. CokerA. MatthewsR. de BoerA. Yazar-KlosinskiB. EmersonA. DoblinR. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.Nat. Med.20212761025103310.1038/s41591‑021‑01336‑333972795
     [Google Scholar]
  67. RudnickG. WallS.C. The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.Proc. Natl. Acad. Sci. USA19928951817182110.1073/pnas.89.5.18171347426
     [Google Scholar]
  68. HakeH.S. DavisJ.K.P. WoodR.R. TannerM.K. LoetzE.C. SanchezA. OstrovskyyM. OlesonE.B. GrigsbyJ. DoblinR. GreenwoodB.N. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats.Physiol. Behav.201919934335010.1016/j.physbeh.2018.12.00730529341
     [Google Scholar]
  69. NardouR. LewisE.M. RothhaasR. XuR. YangA. BoydenE. DölenG. Oxytocin-dependent reopening of a social reward learning critical period with MDMA.Nature2019569775411612010.1038/s41586‑019‑1075‑930944474
     [Google Scholar]
  70. DossM.K. WeaferJ. GalloD.A. de WitH. MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections.Neuropsychopharmacology201843479180010.1038/npp.2017.17128825422
     [Google Scholar]
  71. UnützerJ. ParkM. Older adults with severe, treatment-resistant depression.JAMA2012308990991810.1001/2012.jama.1069022948701
     [Google Scholar]
  72. TetsukaS. Depression and dementia in older adults: A neuropsychological review.Aging Dis.20211281920193410.14336/AD.2021.052634881077
     [Google Scholar]
  73. van MarumR.J. Underrepresentation of the elderly in clinical trials, time for action.Br. J. Clin. Pharmacol.202086102014201610.1111/bcp.1453932909294
     [Google Scholar]
  74. JohnstonC.B. ManginiM. GrobC. AndersonB. The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns.Am. J. Geriatr. Psychiatry2023311445310.1016/j.jagp.2022.08.00736184377
     [Google Scholar]
  75. Breakthrough Therapy.2018Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
  76. ReardonS. MDMA therapy for PTSD rejected by FDA panel.Nature202410.1038/d41586‑024‑01622‑338844808
     [Google Scholar]
  77. ArmstrongS.B. DavisA.K. Psychedelic research at a crossroads.Science20243856715125510.1126/science.adt102439298596
     [Google Scholar]
  78. WolfgangA.S. HogeC.W. Psychedelic-assisted therapy in military and veterans healthcare systems: Clinical, legal, and implementation considerations.Curr. Psychiatry Rep.2023251051353210.1007/s11920‑023‑01446‑437682446
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673359474250511181821
Loading
MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years
Curr. Med. Chem. 33, 1178 (2026); https://doi.org/10.2174/0109298673359474250511181821
/content/journals/cmc/10.2174/0109298673359474250511181821
/content/journals/cmc/10.2174/0109298673359474250511181821
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): literature analysis; MDMA; oxytocin; PTSD; PubMed; scopus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test